Seeking Pioneers in Germany: Real-World ARA/DHA Use in Preterm Infants

A new implementation project is set to begin across several high-volume NICUs in Germany, focusing on the use of NeoMega36® — a supplement containing arachidonic acid (ARA) and docosahexaenoic acid (DHA) — for extremely preterm infants.

The study will run for eight months and include data collection on tolerance, usability and clinical efficacy. Participating NICUs will recruit infants born before 28 weeks of gestation to gather real-world insights from clinical settings.

The study will collect data on tolerance, usability, and clinical efficacy, providing valuable real-world evidence to support broader implementation. Upon completion, results will be submitted for publication in a peer-reviewed journal.

The project is coordinated by Neobiomics in collaboration with local clinical teams. Results will be analysed and submitted for publication following study completion.

More updates will follow as the study progresses.

Please contact info@neobiomics.eu if you would like to participate or want to hear more about the project.